Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer

Karen A. Autio; Robert Dreicer; Justine Anderson; Jorge A. García; Ajjai Alva; Lowell L. Hart; Matthew I. Milowsky; Edwin M. Posadas; Charles J. Ryan; Ryon P. Graf; Ryan Dittamore; Nicole A. Schreiber; Jason M. Summa; Hagop Youssoufian; Michael J. Morris; Howard I. Scher

doi:10.1001/jamaoncol.2018.2168

July 6, 2018JAMA OncologyOpen Access

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer

View Full Paper

Ask AI

Bookmark

Share

Key Points

To assess the safety, tolerability, and therapeutic efficacy of BIND-014, a PSMA-targeted docetaxel nanoparticle, in patients with metastatic castration-resistant prostate cancer.
Conducted an interventional clinical trial evaluating BIND-014 docetaxel nanoparticles in patients with metastatic castration-resistant prostate cancer (ClinicalTrials.gov: NCT01812746).
Monitored safety parameters, adverse events, and antitumor activity following targeted nanoparticle administration.
Evaluated clinical response rates and safety outcomes for targeted nanoparticle delivery in metastatic disease.
Specific quantitative safety and efficacy metrics are tracked under clinical trial identifier NCT01812746.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Clinical trial evaluates safety and efficacy of PSMA-targeted docetaxel nanoparticles in metastatic castration-resistant prostate cancer, highlighting targeted nanotherapy approaches.

Abstract

ClinicalTrials.gov Identifier: NCT01812746.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Autio et al. (2018) studied this question.

synapsesocial.com/papers/69dd1692a6f240e91f1336ba https://doi.org/10.1001/jamaoncol.2018.2168

View Full Paper

Ask AI

Bookmark

Share

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading